ArticleBrain and behavior2025
Genetic Liability to Bone Mineral Density and Functional Outcome After Ischemic Stroke.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Liability to Bone Mineral Density and Functional Outcome After Ischemic Stroke.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesAn increasing amount of research indicates that bone mineral density (BMD) could impact the functional outcome after ischemic stroke (FOAIS). However, the specific connection between BMD and FOAIS is still not clear. Hence, we utilized the Mendelian randomization method to examine the genetic predisposition to BMD in connection with FOAIS.
methodsInstrumental variables for BMD, heel bone mineral density T score (HBMDTS), and lumbar spine bone mineral density (LSBMD) were identified from genome-wide association study data of individuals with European ancestry. The study on FOAIS data came from European ancestry patients and was carried out by the Genetics of Ischemic Stroke (IS) Functional Outcome network. The inverse variance weighted method was employed to assess the genetic correlation between BMD and FOAIS. To assess the reliability of the results, sensitivity analyses were performed employing alternative Mendelian randomization techniques, such as the weighted median approach and MR analysis using the Robust Adjusted Profile Score. Furthermore, the intercept from MR-Egger regression was applied to identify possible pleiotropic effects. The variability among genetic variants was evaluated through I
resultsGenetic liability to HBMDTS was associated with poor FOAIS at 3 months (mRS 3-6, IVW OR = 1.30; 95% CI = 1.09-1.54; p = 0.003, p-Bonferroni = 0.009). Even after adjusting for relevant factors, significant associations remained (mRS 3-6, IVW OR = 1.33; 95% CI = 1.09-1.63; p = 0.006, p-Bonferroni = 0.017). No significant causal effects were observed for total BMD or LSBMD on FOAIS. Sensitivity analyses showed no evidence of pleiotropy or heterogeneity.
conclusionsGenetic predisposition to HBMDTS was associated with poor FOAIS. This research provides a genetic basis for the association between HBMDTS and poor FOAIS, potentially impacting the clinical significance of recovery for stroke patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.